Group 1: Institutional Investment Activity - Almitas Capital LLC acquired 946,323 shares of Geron Corporation, valued at approximately $1,296,000, representing about 0.15% ownership [2] - Soleus Capital Management L.P. increased its position in Geron by 572.5%, owning 16,140,000 shares worth $22,757,000 after acquiring an additional 13,740,000 shares [2] - Squarepoint Ops LLC grew its position by 157.1%, now owning 3,599,221 shares valued at $5,075,000 after acquiring 2,199,413 shares [2] - Two Sigma Investments LP purchased a new stake worth approximately $2,537,000 in the third quarter [2] - Vestal Point Capital LP increased its stake by 8.0%, now owning 23,775,000 shares worth $33,523,000 after purchasing 1,769,660 shares [2] - Candriam S.C.A. raised its stake by 71.6%, owning 3,253,960 shares valued at $4,458,000 after acquiring 1,358,068 shares [2] - 73.71% of Geron's stock is owned by hedge funds and institutional investors [2] Group 2: Financial Performance - Geron reported earnings of ($0.05) per share, missing analysts' consensus estimates of ($0.03) by ($0.02) [3] - The company had revenue of $48.02 million, below analysts' expectations of $50.43 million [3] - Geron has a negative net margin of 46.65% and a negative return on equity of 28.86% [3] - The company is forecasted to post -0.25 EPS for the current year [3] Group 3: Stock Performance and Ratings - Geron shares opened at $1.58, with a 50-day simple moving average of $1.52 and a 200-day simple moving average of $1.36 [3] - The company has a market cap of $1.01 billion, a P/E ratio of -12.15, and a beta of 0.58 [3] - Geron's stock has a 1-year low of $1.04 and a 1-year high of $2.01 [3] - The consensus rating for Geron is "Hold" with an average price target of $2.17 [4] - Two analysts rated the stock as Buy, three as Hold, and two as Sell [4] Group 4: Company Overview - Geron Corporation is a clinical-stage biotechnology company focused on developing treatments targeting telomerase, an enzyme linked to cancer cell immortality [5] - The company's research targets hematologic malignancies and solid tumors, aiming to address diseases with limited therapeutic options [5] - The lead product candidate, imetelstat, is a first-in-class telomerase inhibitor currently in Phase II and Phase III clinical trials for myelofibrosis and myelodysplastic syndromes [6]

Core Insights - Geron is focusing on the commercialization of imetelstat, a drug aimed at lower-risk MDS patients, which is seen as a significant opportunity for the company [3] - In its first full commercial year, Geron reported sales of $184 million, indicating a strong market entry [4] Company Strategy - The company is refining its commercialization plan to reach more patients effectively [3] - The leadership believes that the drug has the potential to make a meaningful difference in patient outcomes [3] Leadership Experience - The CEO, Harout Semerjian, has over 30 years of experience in the pharmaceutical and biotech industries, particularly in hematology and oncology [3]

Core Insights - Geron is focusing on RYTELO as a standard-of-care option for second-line patients, emphasizing its market potential in lower-risk myelodysplastic syndromes (MDS) [1][3] - The company is implementing a "3D surround sound" marketing strategy, increasing investment in effective channels such as digital promotion and educational platforms [1][2] - Geron anticipates RYTELO net revenue of $220 million to $240 million for 2026, with consistent quarter-over-quarter demand growth expected [5] Commercial Performance - RYTELO's fourth-quarter 2025 net revenue was $48 million, aligning with expectations, while the full-year revenue reached $184 million [6] - Demand for RYTELO grew by 9% in the fourth quarter compared to the third quarter, with a 13% increase in prescribing accounts, expanding to approximately 1,300 accounts [4][6] - The company reported that first- and second-line patient starts were about 30% on a rolling 12-month basis [4] Market Dynamics - Geron sees favorable market conditions for second-line, lower-risk MDS, with an estimated eligible patient population of around 8,000 in the U.S. [3] - The competitive landscape is shifting, with key opinion leaders preferring imetelstat over ESAs as a second-line option due to the dominance of luspatercept in the first line [8] Financial Overview - Total operating expenses for 2025 were approximately $255 million, with guidance for 2026 set at $230 million to $240 million, reflecting a year-over-year reduction [13][14] - The company has access to an additional $125 million in capital through an amendment to its loan agreement, with plans for a new shelf registration [14] Research and Development - Geron is supporting over 10 investigator-sponsored trials and real-world evidence initiatives, with initial data expected in the second half of 2026 [10][11] - The IMpactMF trial is fully enrolled and projected to reach its interim analysis in the second half of this year, with overall survival as the primary endpoint [12] International Strategy - Geron has received European approval for RYTELO but is cautious about its near-term impact due to funding limitations [16] - The company is focused on U.S. growth while exploring opportunities in Europe, including understanding health technology assessment processes [16]

Financial Data and Key Metrics Changes - RYTELO's fourth quarter net revenue was $48 million, consistent with expectations, while full year 2025 net revenue reached $184 million, a significant increase from $76 million in 2024 [7][18]. - Total operating expenses for 2025 were approximately $255 million, aligning with previous guidance of $250 million-$260 million [8][21]. - Gross to net deductions increased to 17.7% for the year ending December 31, 2025, compared to 14.5% for the previous year [19]. - The company expects RYTELO net revenue for 2026 to be between $220 million and $240 million, with total operating expenses projected to be between $230 million and $240 million, reflecting a year-over-year reduction at the midpoint [8][23]. Business Line Data and Key Metrics Changes - RYTELO achieved a 9% demand growth in Q4 2025 compared to Q3, with a 13% increase in prescribing accounts, expanding to approximately 1,300 accounts [10]. - First and second-line patient starts on a rolling 12-month basis were at 30%, indicating favorable market conditions for RYTELO in second-line, lower-risk MDS [10]. Market Data and Key Metrics Changes - The primary commercial focus for 2026 is on approximately 8,000 eligible second-line, lower-risk MDS patients in the U.S., with RYTELO's broad label supporting treatment across various lines of therapy [12]. - The recent NCCN guidelines have positioned RYTELO as a preferred second-line agent, enhancing its market opportunity [33]. Company Strategy and Development Direction - The company aims to become a hematology powerhouse, focusing on a more commercially minded organization and improving financial discipline [5]. - RYTELO's growth strategy includes increasing awareness among healthcare professionals and expanding research partnerships within the U.S. hematology community [5][6]. - The company is pursuing pathways to bring RYTELO to patients outside the U.S. while maintaining financial discipline to evaluate opportunistic innovation [25]. Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in RYTELO's revenue growth strategy and operational execution, emphasizing the importance of consistent quarter-over-quarter demand growth [8][9]. - The strategic restructuring completed in December 2025 is expected to position the company for growth in 2026, with a focus on operational execution and delivering value to patients [21][23]. Other Important Information - As of December 31, 2025, the company had approximately $400 million in cash equivalents, restricted cash, and marketable securities, down from $503 million the previous year [22]. - The company plans to file a new shelf registration and ATM with its 10-K on February 27 [23]. Q&A Session Summary Question: What commercial or physician behavioral milestones should be watched for in the first half of the year? - Management highlighted Q4 demand growth of 9% as an important forward-looking metric and reiterated guidance for growth between $220 million and $240 million for 2026 [28][29]. Question: How many second-line patients are currently targeted, and what is the proportion to third-line patients? - Management indicated a focus on approximately 8,000 second-line patients, with a significant shift in treatment paradigms favoring RYTELO over HMAs [32][33]. Question: What is the expected cadence for demand growth to translate into revenue? - Management noted that demand growth and revenue are interconnected, with a focus on increasing patient access and account engagement [35][37]. Question: Is there a path to profitability in 2026? - Management acknowledged a potential path to profitability but emphasized that the focus for 2026 is on making impactful investments rather than immediate profitability [45]. Question: What are the plans regarding European approval and market strategy? - Management confirmed ongoing efforts to understand HTA processes and negotiate pricing while maintaining a strong focus on U.S. growth [63][65].

Financial Data and Key Metrics Changes - RYTELO's fourth quarter net revenue was $48 million, consistent with expectations, while full year 2025 net revenue reached $184 million, a significant increase from $76 million in 2024 [5][17] - Total operating expenses for 2025 were approximately $255 million, aligning with previous guidance of $250 million-$260 million [6][20] - Gross to net deductions increased to 17.7% for the year, up from 14.5% the previous year, with expectations for 2026 to be in the high teens to low twenties [18] Business Line Data and Key Metrics Changes - RYTELO achieved a 9% demand growth in Q4 compared to Q3, with a 13% increase in prescribing accounts, expanding to approximately 1,300 accounts [8][10] - The company is focusing on second-line, lower-risk MDS patients, estimating around 8,000 eligible patients in the U.S. [10][32] Market Data and Key Metrics Changes - The market opportunity for RYTELO is validated by IMerge data, FDA label, and NCCN guidelines, indicating favorable conditions for second-line treatment [6][10] - The shift of luspatercept to the first-line setting has clarified the second-line opportunity for RYTELO [8][32] Company Strategy and Development Direction - The company aims to become a hematology powerhouse, focusing on a refined commercial strategy and improved financial discipline [4] - Key initiatives include targeted engagement with high-volume community accounts and increased investment in effective marketing channels [9][10] - The company plans to pursue pathways to bring RYTELO to patients outside the U.S. while maintaining financial discipline [24] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in RYTELO's revenue growth strategy and operational execution, reiterating guidance for 2026 net revenue of $220 million-$240 million [6][21] - The strategic restructuring completed in December 2025 is expected to position the company for growth in 2026 [20][21] Other Important Information - The company has approximately $400 million in cash equivalents and marketable securities as of December 31, 2025, down from $503 million the previous year [20] - A recent amendment to the Pharmakon loan agreement extends access to an additional $125 million in capital through July 30, 2026 [21] Q&A Session Summary Question: Insights on commercial or physician behavioral milestones for growth - Management highlighted Q4 demand growth of 9% as an important forward-looking metric and noted that they are focused on execution and refined messaging to drive growth [26][28] Question: Current second-line patient numbers and their proportion to third-line patients - Management indicated they are targeting approximately 8,000 second-line patients and emphasized the importance of focusing on this segment for growth [31][32] Question: Cadence of demand growth translating into revenue - Management explained that demand growth is crucial for increasing patient numbers and that they are focused on high-volume community accounts to drive consistent growth [35][37] Question: Potential for breaking even and thoughts on profitability - Management sees a path to profitability but emphasizes that the focus for 2026 is on making the right investments rather than immediate profitability [40][44] Question: Role of EPO as a second-line competitor - Management noted that with luspatercept moving to first-line treatment, the role of ESAs is diminishing, and imetelstat is becoming the preferred second-line option [54][59] Question: Plans for European approval and strategy - Management acknowledged the need to understand HTA processes and pricing strategies in Europe while maintaining a strong focus on U.S. growth [60][64]

Summary of Geron (NasdaqGS: GERN) FY Conference Call - December 02, 2025 Company Overview - **Company**: Geron Corporation - **Product**: Rytello (imetelstat), a first-in-class telomerase inhibitor targeting low-risk myelodysplastic syndromes (MDS) patients - **Sales Performance**: Reported $47.2 million in net sales in the U.S. for the last quarter, marking five quarters since launch [3][4][32] Key Points and Arguments Product Efficacy and Market Position - Rytello has demonstrated strong efficacy in clinical trials, particularly in durability and transfusion independence [4][10] - Despite strong clinical data, commercial uptake has been modest compared to expectations, especially when compared to competitors like Luspatercept, which generates over $2 billion annually [4][5] - The company aims to improve uptake by focusing on operational excellence and ensuring the right patients are prescribed Rytello [5][6] Market Strategy and Growth Potential - The company plans to target earlier lines of therapy to drive growth in 2026, moving from later-line patients to second-line patients as indicated by the IMerge study [7][9] - The NCCN guidelines have been updated to position Rytello favorably in relation to other therapies, enhancing its market potential [10] - The company has seen an increase in new accounts, with 1,150 accounts now ordering Rytello, up by 150 from the previous quarter [17] Challenges and Solutions - A significant challenge is the lack of awareness among U.S. physicians regarding Rytello, as most pivotal trial enrollments were conducted outside the U.S. [8][9] - The company is working to build relationships with key opinion leaders (KOLs) and ensure effective communication of trial data [11][12] - Engagement with academic medical centers (AMCs) is crucial, as these institutions are more likely to conduct their own experiments and publish results [21][22] Financial Management and Operational Efficiency - Geron has reduced its operational expenditure (OpEx) guidance for the year to between $250 million and $260 million, emphasizing the need for disciplined spending [32][33] - The company is focused on targeted investments rather than broad spending, aiming to maximize the impact of its resources [33][34] Future Outlook - The IMpactMF trial for myelofibrosis is fully enrolled, with interim analysis expected in H2 2026 and full analysis in H2 2028 [31] - The trial design aims to demonstrate that Rytello can transform myelofibrosis from a deadly disease to a manageable one, potentially doubling the addressable patient market [29][31] Additional Important Insights - The company is addressing concerns regarding cytopenia associated with Rytello, emphasizing the importance of managing this side effect to maintain patient adherence to therapy [25][26] - The focus on tailored messaging for different physician groups is critical for successful commercialization, particularly in the community setting [23][24] This summary encapsulates the key discussions and insights from the Geron FY Conference Call, highlighting the company's strategic direction, challenges, and future growth potential in the oncology market.

Summary of Geron Corporation Conference Call Company Overview - **Company**: Geron Corporation - **Core Asset**: Imetelstat (commercial name: Rytelo), the first approved telomerase inhibitor for lower-risk myelodysplastic syndromes (MDS) [2][5] Key Points Company and Product Positioning - Geron is a commercial-stage hematology company with an approved product, Rytelo, launched in the US and approved in Europe [2][5] - The company aims to help patients in the relapse, lower-risk MDS population, which has limited treatment options [2][5] Leadership and Experience - Harout Semerjian, the new CEO, has over 30 years of experience in biopharma, particularly in oncology and hematology [4][5] - The CEO's previous experience includes launching multiple oncology drugs, which aligns with Geron's current needs [4][5] Market Performance and Challenges - Rytelo's growth has stalled, with net revenue around $50 million, despite strong phase 3 data [6][9] - The disconnect between the drug's efficacy and sales performance is attributed to: - Initial patient selection being primarily late-line patients, who are harder to treat [8][9] - Limited clinical experience among US hematologists at launch, as most trial data was generated outside the US [9][10] Strategic Initiatives - The company is focusing on increasing awareness and education among physicians about Rytelo's efficacy and appropriate patient management [12][13] - Efforts are being made to shift Rytelo's utilization from later lines of treatment to earlier lines, as indicated by clinical guidelines [12][21] Patient Population and Treatment Dynamics - The real-world patient population primarily consists of third-line and fourth-line patients, which affects treatment duration and outcomes [17][18] - The NCCN guidelines have recently been updated to position Rytelo favorably in treatment protocols, moving it ahead of other therapies like HMAs [18][19][21] Competitive Landscape - Luspatercept's approval as a front-line therapy for RS-positive patients may impact patient flow into later lines of treatment, creating opportunities for Rytelo as a second-line option [30][31] - Physicians' treatment decisions are influenced by baseline transfusion burden, with Rytelo being the only effective option for heavily transfused patients [37][38] Future Outlook - Geron anticipates growth in 2026, supported by a robust cash balance and strategic initiatives aimed at enhancing market presence [11][40][41] - The company has submitted five abstracts for the upcoming ASH conference, including data on cytopenia correlating with response and long-term survival benefits [41][42] International Expansion - Geron is exploring commercialization plans in Europe, including launching under named patient programs and engaging in HTA conversations [50][51] Additional Insights - The company is committed to educating the market about Rytelo's unique mechanism of action and the importance of managing cytopenias effectively [40][41] - There is a focus on building partnerships with both community and academic medical centers to enhance Rytelo's adoption [27][28]

Group 1: Geron Corporation (GERN) - A shareholder class action lawsuit has been filed against Geron Corporation, alleging that the company disseminated materially false and/or misleading statements and concealed material adverse facts regarding Rytelo's (imetelstat) potential between February 28, 2024, and February 25, 2025 [1] - Investors who purchased Geron shares during this period and suffered significant losses are encouraged to discuss their legal rights [1] Group 2: Fluence Energy, Inc. (FLNC) - A shareholder class action lawsuit has been filed against Fluence Energy, Inc., alleging that the company made materially false and/or misleading statements and failed to disclose material facts regarding its relationship with founders Siemens AG and The AES Corporation between October 28, 2021, and February 10, 2025 [2] - Investors who purchased Fluence shares during this period and suffered significant losses are encouraged to discuss their legal rights [2] Group 3: Holzer & Holzer, LLC - Holzer & Holzer, LLC is a top-rated securities litigation law firm that focuses on representing shareholders and investors in litigation, including shareholder class action and derivative litigation [3] - Since its founding in 2000, the firm has played critical roles in recovering hundreds of millions of dollars for shareholders affected by fraud and corporate misconduct [3]

Core Viewpoint - Geron Corporation is facing a class action lawsuit for alleged violations of the Securities Exchange Act of 1934, with claims that the company and its executives misled investors regarding the performance and market potential of its primary product, Rytelo [1][3]. Company Overview - Geron Corporation is a commercial-stage biopharmaceutical company focused on developing therapeutic products for oncology, with its main product being a telomerase inhibitor called imetelstat, marketed as Rytelo [2]. Allegations of the Lawsuit - The lawsuit alleges that Geron and its executives made false or misleading statements about the company's revenue outlook and growth potential, downplaying risks associated with seasonality and macroeconomic factors [3]. - It is claimed that the optimistic reports regarding Rytelo's launch success did not reflect the reality of market conditions, including competition and the need for ongoing monitoring of the treatment [3]. - The lawsuit further asserts that Rytelo lacked sufficient market awareness, hindering Geron's ability to meet the significant unmet need for the drug, particularly among first-line patients [3]. Financial Impact - Following the announcement of Geron's fourth-quarter financial results for fiscal year 2024 on February 26, 2025, which indicated a flattening growth for Rytelo, the company's stock price dropped by over 32% [4].

Core Viewpoint - Geron Corporation is facing a class action lawsuit for alleged violations of the Securities Exchange Act of 1934, with claims that the company and its executives misled investors regarding the performance and market potential of its primary product, Rytelo [1][3]. Company Overview - Geron Corporation is a commercial-stage biopharmaceutical company focused on developing therapeutic products for oncology, with its main product being a telomerase inhibitor called imetelstat, marketed as Rytelo [2]. Allegations of the Lawsuit - The lawsuit alleges that Geron and its executives made false or misleading statements about the company's revenue outlook and growth potential, downplaying risks associated with seasonality and macroeconomic factors [3]. - It is claimed that the optimistic reports regarding Rytelo's launch success did not reflect the reality of its market penetration challenges, including competition and a lack of awareness among potential patients [3]. - Following the announcement of financial results for Q4 2024, which indicated stagnant growth for Rytelo, Geron's stock price dropped over 32%, highlighting the impact of the alleged misrepresentations [4]. Legal Process - Investors who purchased Geron securities during the specified class period can seek to be appointed as lead plaintiff in the class action lawsuit, representing the interests of all class members [5]. Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder litigation, having secured over $2.5 billion for investors in 2024 alone [6].